| Chronic osteomyelitis: a review on current concepts and trends in treatment A Barakat, WHK Schilling, S Sharma, E Guryel, R Freeman Orthopaedics and Trauma 33 (3), 181-187, 2019 | 47 | 2019 |
| Blood culture negative endocarditis in the modern era of 16S rRNA sequencing R Godfrey, S Curtis, WHK Schilling, PR James Clinical Medicine 20 (4), 412-416, 2020 | 43 | 2020 |
| Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled … WHK Schilling, P Jittamala, JA Watson, S Boyd, V Luvira, T Siripoon, ... The Lancet Infectious Diseases 24 (1), 36-45, 2024 | 26 | 2024 |
| Automating the generation of antimicrobial resistance surveillance reports: proof-of-concept study involving seven hospitals in seven countries C Lim, T Miliya, V Chansamouth, MT Aung, A Karkey, P Teparrukkul, ... Journal of medical Internet research 22 (10), e19762, 2020 | 23 | 2020 |
| Defining the burden of febrile illness in rural South and Southeast Asia: an open letter to announce the launch of the Rural Febrile Illness project A Chandna, R Chew, NSN Htun, TJ Peto, M Zhang, M Liverani, ... Wellcome open research 6, 2021 | 20 | 2021 |
| Does hydroxychloroquine still have any role in the COVID-19 pandemic? WHK Schilling, NJ White Expert Opinion on Pharmacotherapy 22 (10), 1257-1266, 2021 | 15 | 2021 |
| Cutaneous stigmata associated with insulin resistance and increased cardiovascular risk WHK Schilling, MA Crook International Journal of Dermatology 53 (9), 1062-1069, 2014 | 14 | 2014 |
| The WHO guideline on drugs to prevent COVID-19: small numbers-big conclusions WHK Schilling, JJ Callery, A Chandna, RL Hamers, JA Watson, NJ White Wellcome open research 6, 2021 | 11 | 2021 |
| Pharmacometrics of high dose ivermectin in early COVID-19: an open label, randomized, controlled adaptive platform trial (PLATCOV) WHK Schilling, P Jittamala, JA Watson, M Ekkapongpisit, T Siripoon, ... Elife 12, 2023 | 10 | 2023 |
| No evidence that chloroquine or hydroxychloroquine induce hemolysis in G6PD deficiency WHK Schilling, G Bancone, NJ White Blood cells, molecules & diseases 85, 102484, 2020 | 9 | 2020 |
| Clinical antiviral efficacy of favipiravir in early COVID-19 (PLATCOV): an open-label, randomised, controlled, adaptive platform trial V Luvira, WHK Schilling, P Jittamala, JA Watson, S Boyd, T Siripoon, ... BMC Infectious Diseases 24 (1), 89, 2024 | 8 | 2024 |
| Clinical antiviral efficacy of remdesivir in coronavirus disease 2019: an open-label, randomized controlled adaptive platform trial (PLATCOV) P Jittamala, WHK Schilling, JA Watson, V Luvira, T Siripoon, ... The Journal of Infectious Diseases 228 (10), 1318-1325, 2023 | 8 | 2023 |
| Antimicrobial resistance patterns in bacteria causing febrile illness in Africa, South Asia, and Southeast Asia: a systematic review of published etiological studies from 1980-2015 T Roberts, P Dahal, P Shrestha, W Schilling, R Shrestha, R Ngu, ... International Journal of Infectious Diseases 122, 612-621, 2022 | 7 | 2022 |
| Clinical antiviral efficacy of remdesivir and casirivimab/imdevimab against the SARS-CoV-2 Delta and Omicron variants P Jittamala, WHK Schilling, JA Watson, V Luvira, T Siripoon, ... medRxiv, 2022.10. 17.22281161, 2022 | 5 | 2022 |
| Pharmacometric assessment of the in vivo antiviral activity of ivermectin in early symptomatic COVID-19 WHK Schilling, P Jittamala, JA Watson, M Ekkapongpisit, T Siripoon, ... medRxiv, 2022.07. 15.22277570, 2022 | 5 | 2022 |
| Chloroquine/hydroxychloroquine prevention of coronavirus disease (COVID-19) in the healthcare setting; protocol for a randomised, placebo-controlled prophylaxis study (COPCOV) WH Schilling, JJ Callery, W Taylor, M Mukaka, M Ekkapongpisit, ... Wellcome open research 5 (241), 241, 2020 | 3 | 2020 |
| Twelve year analysis of aerobic-only blood cultures for routine detection of bacteraemia S Stoneham, W Schilling, A San Francisco, M Llewelyn Journal of Hospital Infection 104 (4), 592-596, 2020 | 3 | 2020 |
| The relationship between viral clearance rates and disease progression in early symptomatic COVID-19: a systematic review and meta-regression analysis S Singh, S Boyd, WHK Schilling, JA Watson, M Mukaka, NJ White Journal of Antimicrobial Chemotherapy, dkae045, 2024 | 2 | 2024 |
| Temporal changes in SARS-CoV-2 clearance kinetics and the optimal design of phase 2 antiviral studies P Wongnak, WHK Schilling, P Jittamala, SHK Boyd, V Luvira, T Siripoon, ... | 2 | 2024 |
| Antiviral efficacy of fluoxetine in early symptomatic COVID-19: An open-label, randomised, controlled, adaptive platform trial (PLATCOV) P Jittamala, S Boyd, WHK Schilling, JA Watson, T Ngamprasertchai, ... medRxiv, 2024.01. 16.24301337, 2024 | 2 | 2024 |
